Evidence map›Paper›PMID 27356752›Full record

ArticleOncotarget2016

The modulation of Dicer regulates tumor immunogenicity in melanoma.

Nicholas C Hoffend, William J Magner, Thomas B Tomasi

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Nicholas C HoffendLaboratory of Molecular Medicine, Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA.
William J MagnerLaboratory of Molecular Medicine, Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA.
Thomas B TomasiLaboratory of Molecular Medicine, Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA.
Roswell Park Comprehensive Cancer Center · USUniversity at Buffalo, State University of New York · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Epigenetic Regulation of Immune Genes in Cancer Treatment and Vaccine ProtocolsR01CA124971 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI TOMASI, THOMAS B · 2008 to 2011
$1.3M
NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA124971
6 · The paper itself

Abstract

MicroRNAs (miRs) are small non-coding RNAs that regulate most cellular protein networks by targeting mRNAs for translational inhibition or degradation. Dicer, a type III endoribonuclease, is a critical component in microRNA biogenesis and is required for mature microRNA production. Abnormal Dicer expression occurs in numerous cancer types and correlates with poor patient prognosis. For example, increased Dicer expression in melanoma is associated with more aggressive tumors (higher tumor mitotic index and depth of invasion) and poor patient prognosis. However, the role that Dicer plays in melanoma development and immune evasion remains unclear. Here, we report on a newly discovered relationship between Dicer expression and tumor immunogenicity. To investigate Dicer's role in regulating melanoma immunogenicity, Dicer knockdown studies were performed. We found that B16F0-Dicer deficient cells exhibited decreased tumor growth compared to control cells and were capable of inducing anti-tumor immunity. The decrease in tumor growth was abrogated in immunodeficient NSG mice and was shown to be dependent upon CD8+ T cells. Dicer knockdown also induced a more responsive immune gene profile in melanoma cells. Further studies demonstrated that CD8+ T cells preferentially killed Dicer knockdown tumor cells compared to control cells. Taken together, we present evidence which links Dicer expression to tumor immunogenicity in melanoma.

Indexed as

AnimalsCD8-Positive T-LymphocytesCell Line, TumorDEAD-box RNA HelicasesFemaleMaleMelanoma, ExperimentalMiceMice, Inbred C57BLMicroRNAsPrognosisRibonuclease IIIDEAD-box RNA HelicasesDicer1 protein, mouseMicroRNAsRibonuclease IIICD8+ T cellsDicerimmunogenicitymelanomamicroRNA

Identifiers

PMID27356752
PMCPMC5216969
OpenAlexW2473605640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.